# A Phase II Study Of Imtox-25 In Adults With Refractory/Relapsed Cd25 Positive Adult T Cell Leukemia/Lymphoma

> **NCT01378871** · PHASE2 · TERMINATED · sponsor: **Amit Verma** · enrollment: 1 (actual)

## Conditions studied

- Adult T Cell Leukemia
- Adult T Cell Lymphoma

## Interventions

- **DRUG:** IMTOX-25

## Key facts

- **NCT ID:** NCT01378871
- **Lead sponsor:** Amit Verma
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-09
- **Primary completion:** 2013-01
- **Final completion:** 2013-01
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** IND withdrawn
- **Last updated:** 2023-06-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01378871

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01378871, "A Phase II Study Of Imtox-25 In Adults With Refractory/Relapsed Cd25 Positive Adult T Cell Leukemia/Lymphoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01378871. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*